Haruka Onoue1,2, Ikuko Yano3,4, Atsuko Tanaka1,2, Kotaro Itohara1,2, Akiko Hanai5, Hiroshi Ishiguro6, Hideyuki Motohashi2, Satohiro Masuda2, Kazuo Matsubara2. 1. Department of Clinical Pharmacy and Education, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, 606-8501, Japan. 2. Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan. 3. Department of Clinical Pharmacy and Education, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, 606-8501, Japan. iyano@kuhp.kyoto-u.ac.jp. 4. Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan. iyano@kuhp.kyoto-u.ac.jp. 5. Departmant of Human Sciences, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, 606-8501, Japan. 6. Department of Target Therapy Oncology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, 606-8507, Japan.
Abstract
PURPOSE: Docetaxel is frequently used in the treatment of a wide variety of solid tumors, including breast cancer. The aim of this study is to obtain the population pharmacokinetic parameters of docetaxel in Japanese female patients with breast cancer. METHODS: Blood samples from 24 patients were collected sequentially before and after docetaxel infusion. Genomic DNA was isolated from the peripheral blood and genotyped for the selected polymorphisms in the candidate genes of drug transporters and metabolizing enzymes. The influence of patient characteristics on the pharmacokinetics of docetaxel was evaluated using the nonlinear-mixed-effect modeling program, NONMEM. As a basis for comparison, the pharmacokinetics of another taxane paclitaxel in 41 separate female patients with breast cancer was calculated. RESULTS: A two-compartment model adequately described the pharmacokinetic profiles of docetaxel. The population mean estimates of the total body clearance for patients aged 58 years or less and the central volume of distribution for docetaxel were 32.6 L/h and 5.77 L, respectively. In patients over 58 years, the clearance was 24 % higher than that in the younger patients. No influences of the genotypes examined were noted on the clearance of docetaxel. The clearance of paclitaxel was not affected by patient age. CONCLUSIONS: Patients over the age of 58 years showed significantly higher clearance of docetaxel than that in patients aged 58 years or less. Since the clearance of paclitaxel was not affected by the age, it is possible that the pharmacokinetic mechanisms of docetaxel might be specifically affected by age in females.
PURPOSE:Docetaxel is frequently used in the treatment of a wide variety of solid tumors, including breast cancer. The aim of this study is to obtain the population pharmacokinetic parameters of docetaxel in Japanese female patients with breast cancer. METHODS: Blood samples from 24 patients were collected sequentially before and after docetaxel infusion. Genomic DNA was isolated from the peripheral blood and genotyped for the selected polymorphisms in the candidate genes of drug transporters and metabolizing enzymes. The influence of patient characteristics on the pharmacokinetics of docetaxel was evaluated using the nonlinear-mixed-effect modeling program, NONMEM. As a basis for comparison, the pharmacokinetics of another taxanepaclitaxel in 41 separate female patients with breast cancer was calculated. RESULTS: A two-compartment model adequately described the pharmacokinetic profiles of docetaxel. The population mean estimates of the total body clearance for patients aged 58 years or less and the central volume of distribution for docetaxel were 32.6 L/h and 5.77 L, respectively. In patients over 58 years, the clearance was 24 % higher than that in the younger patients. No influences of the genotypes examined were noted on the clearance of docetaxel. The clearance of paclitaxel was not affected by patient age. CONCLUSIONS:Patients over the age of 58 years showed significantly higher clearance of docetaxel than that in patients aged 58 years or less. Since the clearance of paclitaxel was not affected by the age, it is possible that the pharmacokinetic mechanisms of docetaxel might be specifically affected by age in females.
Entities:
Keywords:
Breast cancer; Docetaxel; Female hormone; Pharmacogenetics; Population pharmacokinetics
Authors: Tessa M Bosch; Alwin D R Huitema; Valerie D Doodeman; Robert Jansen; Els Witteveen; Wim M Smit; Rob L Jansen; Carla M van Herpen; Marcel Soesan; Jos H Beijnen; Jan H M Schellens Journal: Clin Cancer Res Date: 2006-10-01 Impact factor: 12.531
Authors: S Y Hor; S C Lee; C I Wong; Y W Lim; R C Lim; L Z Wang; L Fan; J Y Guo; H S Lee; B C Goh; T Tan Journal: Pharmacogenomics J Date: 2007-09-18 Impact factor: 3.550
Authors: Kjell A Mortier; Vincent Renard; Alain G Verstraete; Annie Van Gussem; Simon Van Belle; Willy E Lambert Journal: Anal Chem Date: 2005-07-15 Impact factor: 6.986
Authors: Kellie A Slaviero; Stephen J Clarke; Andrew J McLachlan; Elaine Y L Blair; Laurent P Rivory Journal: Br J Clin Pharmacol Date: 2004-01 Impact factor: 4.335
Authors: S D Baker; J Verweij; G A Cusatis; R H van Schaik; S Marsh; S J Orwick; R M Franke; S Hu; E G Schuetz; V Lamba; W A Messersmith; A C Wolff; M A Carducci; A Sparreboom Journal: Clin Pharmacol Ther Date: 2008-05-28 Impact factor: 6.875
Authors: M C Launay-Iliadis; R Bruno; V Cosson; J C Vergniol; D Oulid-Aissa; M Marty; M Clavel; M Aapro; N Le Bail; A Iliadis Journal: Cancer Chemother Pharmacol Date: 1995 Impact factor: 3.333
Authors: Ye Won Jeon; Seung Taek Lim; Hongki Gwak; Seon Young Park; Juhee Shin; Hye Sug Han; Young Jin Suh Journal: Ann Surg Treat Res Date: 2021-02-01 Impact factor: 1.859